PittsburghV1, France, Analysis, bibRecord, 000567

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

Identifieur interne : 000567 ( France/Analysis ); précédent : 000566; suivant : 000568

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

Auteurs : Neil L. Berinstein [États-Unis] ; Gregory T. Wolf [États-Unis] ; Paul H. Naylor [États-Unis] ; Lorraine Baltzer [États-Unis] ; James E. Egan [États-Unis] ; Harvey J. Brandwein [États-Unis] ; Theresa L. Whiteside [États-Unis] ; Lynn C. Goldstein [États-Unis] ; Adel El-Naggar [États-Unis] ; Cecile Badoual [France] ; Wolf-Herve Fridman [France] ; J. Michael White [États-Unis] ; John W. Hadden [États-Unis]

Source :

Cancer immunology and immunotherapy [ 0340-7004 ] ; 2012.

RBID : Pascal:12-0259414

Descripteurs français

Pascal (Inist)
- Lymphocyte, Infiltration, Homme, Malade, Cancer de la tête et du cou, Traitement, Immunothérapie, Protocole thérapeutique, Monocyte, Macrophage, Cellule dendritique, Cellule APC, Cytokine.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antigen presenting cell, Cytokine, Dendritic cell, Head and neck cancer, Human, Immunotherapy, Infiltration, Lymphocyte, Macrophage, Monocyte, Patient, Therapeutic protocol, Treatment.

Abstract

Twenty-seven subjects with squamous cell cancer of the head and neck received the neoadjuvant IRX-2 immunotherapy regimen prior to surgery in a Phase 2 trial. Pretreatment tumor biopsies were compared with the primary tumor surgical specimens for lymphocyte infiltration, necrosis and fibrosis, using hematoxylin and eosin stain and immunohistochemistry in 25 subjects. Sections were examined by three pathologists. Relative to pretreatment biopsies, increases in lymphocyte infiltration (LI) were seen using H and E or immunohistochemistry. CD3+ CD4+ T cells and CD20+ B cells were primarily found in the peritumoral stroma and CD3+ CD8₊ T cells and CD68+ macrophages were mainly intratumoral. LI in the surgical specimens were associated with reductions in the primary tumor size. Improved survival at 5 years was correlated with high overall LI in the tumor specimens. Neoadjuvant IRX-2 immunotherapy regimen may restore immune responsiveness presumably by mobilizing tumor infiltrating effector lymphocytes and macrophages into the tumor.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 003F30
to stream PascalFrancis, to step Curation: 000F87
to stream PascalFrancis, to step Checkpoint: 003288
to stream Main, to step Merge: 009574
to stream Main, to step Curation: 008F44
to stream Main, to step Exploration: 008F44
to stream France, to step Extraction: 000567

Links to Exploration step

Pascal:12-0259414

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen</title>
<author><name sortKey="Berinstein, Neil L" sort="Berinstein, Neil L" uniqKey="Berinstein N" first="Neil L." last="Berinstein">Neil L. Berinstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wolf, Gregory T" sort="Wolf, Gregory T" uniqKey="Wolf G" first="Gregory T." last="Wolf">Gregory T. Wolf</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Michigan</s1>
<s2>Ann Arbor, MI</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Michigan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Naylor, Paul H" sort="Naylor, Paul H" uniqKey="Naylor P" first="Paul H." last="Naylor">Paul H. Naylor</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Baltzer, Lorraine" sort="Baltzer, Lorraine" uniqKey="Baltzer L" first="Lorraine" last="Baltzer">Lorraine Baltzer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Egan, James E" sort="Egan, James E" uniqKey="Egan J" first="James E." last="Egan">James E. Egan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brandwein, Harvey J" sort="Brandwein, Harvey J" uniqKey="Brandwein H" first="Harvey J." last="Brandwein">Harvey J. Brandwein</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Whiteside, Theresa L" sort="Whiteside, Theresa L" uniqKey="Whiteside T" first="Theresa L." last="Whiteside">Theresa L. Whiteside</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>University of Pittsburgh, Hillman Cancer Center</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA</wicri:noRegion>
<orgName type="university">Université de Pittsburgh</orgName>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goldstein, Lynn C" sort="Goldstein, Lynn C" uniqKey="Goldstein L" first="Lynn C." last="Goldstein">Lynn C. Goldstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>PhenoPath Laboratories</s1>
<s2>Seattle, WA</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>PhenoPath Laboratories</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="El Naggar, Adel" sort="El Naggar, Adel" uniqKey="El Naggar A" first="Adel" last="El-Naggar">Adel El-Naggar</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>M.D. Anderson Cancer Center, The University of Texas</s1>
<s2>Austin, TX</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Austin, TX</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Badoual, Cecile" sort="Badoual, Cecile" uniqKey="Badoual C" first="Cecile" last="Badoual">Cecile Badoual</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Hopital Europeen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fridman, Wolf Herve" sort="Fridman, Wolf Herve" uniqKey="Fridman W" first="Wolf-Herve" last="Fridman">Wolf-Herve Fridman</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Hopital Europeen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Michael White, J" sort="Michael White, J" uniqKey="Michael White J" first="J." last="Michael White">J. Michael White</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>JMWhite Associates</s1>
<s2>Mt Vernon, WA</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>JMWhite Associates</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hadden, John W" sort="Hadden, John W" uniqKey="Hadden J" first="John W." last="Hadden">John W. Hadden</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0259414</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0259414 INIST</idno>
<idno type="RBID">Pascal:12-0259414</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003F30</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F87</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003288</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003288</idno>
<idno type="wicri:doubleKey">0340-7004:2012:Berinstein N:increased:lymphocyte:infiltration</idno>
<idno type="wicri:Area/Main/Merge">009574</idno>
<idno type="wicri:Area/Main/Curation">008F44</idno>
<idno type="wicri:Area/Main/Exploration">008F44</idno>
<idno type="wicri:Area/France/Extraction">000567</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen</title>
<author><name sortKey="Berinstein, Neil L" sort="Berinstein, Neil L" uniqKey="Berinstein N" first="Neil L." last="Berinstein">Neil L. Berinstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wolf, Gregory T" sort="Wolf, Gregory T" uniqKey="Wolf G" first="Gregory T." last="Wolf">Gregory T. Wolf</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Michigan</s1>
<s2>Ann Arbor, MI</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Michigan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Naylor, Paul H" sort="Naylor, Paul H" uniqKey="Naylor P" first="Paul H." last="Naylor">Paul H. Naylor</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Baltzer, Lorraine" sort="Baltzer, Lorraine" uniqKey="Baltzer L" first="Lorraine" last="Baltzer">Lorraine Baltzer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Egan, James E" sort="Egan, James E" uniqKey="Egan J" first="James E." last="Egan">James E. Egan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brandwein, Harvey J" sort="Brandwein, Harvey J" uniqKey="Brandwein H" first="Harvey J." last="Brandwein">Harvey J. Brandwein</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Whiteside, Theresa L" sort="Whiteside, Theresa L" uniqKey="Whiteside T" first="Theresa L." last="Whiteside">Theresa L. Whiteside</name>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>University of Pittsburgh, Hillman Cancer Center</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pittsburgh, PA</wicri:noRegion>
<orgName type="university">Université de Pittsburgh</orgName>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goldstein, Lynn C" sort="Goldstein, Lynn C" uniqKey="Goldstein L" first="Lynn C." last="Goldstein">Lynn C. Goldstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>PhenoPath Laboratories</s1>
<s2>Seattle, WA</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>PhenoPath Laboratories</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="El Naggar, Adel" sort="El Naggar, Adel" uniqKey="El Naggar A" first="Adel" last="El-Naggar">Adel El-Naggar</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>M.D. Anderson Cancer Center, The University of Texas</s1>
<s2>Austin, TX</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Austin, TX</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Badoual, Cecile" sort="Badoual, Cecile" uniqKey="Badoual C" first="Cecile" last="Badoual">Cecile Badoual</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Hopital Europeen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fridman, Wolf Herve" sort="Fridman, Wolf Herve" uniqKey="Fridman W" first="Wolf-Herve" last="Fridman">Wolf-Herve Fridman</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Hopital Europeen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Michael White, J" sort="Michael White, J" uniqKey="Michael White J" first="J." last="Michael White">J. Michael White</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>JMWhite Associates</s1>
<s2>Mt Vernon, WA</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>JMWhite Associates</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hadden, John W" sort="Hadden, John W" uniqKey="Hadden J" first="John W." last="Hadden">John W. Hadden</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>IRX Therapeutics, Inc</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Cancer immunology and immunotherapy</title>
<title level="j" type="abbreviated">Cancer immunol. immunother.</title>
<idno type="ISSN">0340-7004</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Cancer immunology and immunotherapy</title>
<title level="j" type="abbreviated">Cancer immunol. immunother.</title>
<idno type="ISSN">0340-7004</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antigen presenting cell</term>
<term>Cytokine</term>
<term>Dendritic cell</term>
<term>Head and neck cancer</term>
<term>Human</term>
<term>Immunotherapy</term>
<term>Infiltration</term>
<term>Lymphocyte</term>
<term>Macrophage</term>
<term>Monocyte</term>
<term>Patient</term>
<term>Therapeutic protocol</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphocyte</term>
<term>Infiltration</term>
<term>Homme</term>
<term>Malade</term>
<term>Cancer de la tête et du cou</term>
<term>Traitement</term>
<term>Immunothérapie</term>
<term>Protocole thérapeutique</term>
<term>Monocyte</term>
<term>Macrophage</term>
<term>Cellule dendritique</term>
<term>Cellule APC</term>
<term>Cytokine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Twenty-seven subjects with squamous cell cancer of the head and neck received the neoadjuvant IRX-2 immunotherapy regimen prior to surgery in a Phase 2 trial. Pretreatment tumor biopsies were compared with the primary tumor surgical specimens for lymphocyte infiltration, necrosis and fibrosis, using hematoxylin and eosin stain and immunohistochemistry in 25 subjects. Sections were examined by three pathologists. Relative to pretreatment biopsies, increases in lymphocyte infiltration (LI) were seen using H and E or immunohistochemistry. CD3+ CD4+ T cells and CD20+ B cells were primarily found in the peritumoral stroma and CD3+ CD8<sub>+</sub>
 T cells and CD68+ macrophages were mainly intratumoral. LI in the surgical specimens were associated with reductions in the primary tumor size. Improved survival at 5 years was correlated with high overall LI in the tumor specimens. Neoadjuvant IRX-2 immunotherapy regimen may restore immune responsiveness presumably by mobilizing tumor infiltrating effector lymphocytes and macrophages into the tumor.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
<li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
<li>Pittsburgh</li>
</settlement>
<orgName><li>Université de Pittsburgh</li>
</orgName>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Berinstein, Neil L" sort="Berinstein, Neil L" uniqKey="Berinstein N" first="Neil L." last="Berinstein">Neil L. Berinstein</name>
</noRegion>
<name sortKey="Baltzer, Lorraine" sort="Baltzer, Lorraine" uniqKey="Baltzer L" first="Lorraine" last="Baltzer">Lorraine Baltzer</name>
<name sortKey="Brandwein, Harvey J" sort="Brandwein, Harvey J" uniqKey="Brandwein H" first="Harvey J." last="Brandwein">Harvey J. Brandwein</name>
<name sortKey="Egan, James E" sort="Egan, James E" uniqKey="Egan J" first="James E." last="Egan">James E. Egan</name>
<name sortKey="El Naggar, Adel" sort="El Naggar, Adel" uniqKey="El Naggar A" first="Adel" last="El-Naggar">Adel El-Naggar</name>
<name sortKey="Goldstein, Lynn C" sort="Goldstein, Lynn C" uniqKey="Goldstein L" first="Lynn C." last="Goldstein">Lynn C. Goldstein</name>
<name sortKey="Hadden, John W" sort="Hadden, John W" uniqKey="Hadden J" first="John W." last="Hadden">John W. Hadden</name>
<name sortKey="Michael White, J" sort="Michael White, J" uniqKey="Michael White J" first="J." last="Michael White">J. Michael White</name>
<name sortKey="Naylor, Paul H" sort="Naylor, Paul H" uniqKey="Naylor P" first="Paul H." last="Naylor">Paul H. Naylor</name>
<name sortKey="Whiteside, Theresa L" sort="Whiteside, Theresa L" uniqKey="Whiteside T" first="Theresa L." last="Whiteside">Theresa L. Whiteside</name>
<name sortKey="Wolf, Gregory T" sort="Wolf, Gregory T" uniqKey="Wolf G" first="Gregory T." last="Wolf">Gregory T. Wolf</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Badoual, Cecile" sort="Badoual, Cecile" uniqKey="Badoual C" first="Cecile" last="Badoual">Cecile Badoual</name>
</region>
<name sortKey="Fridman, Wolf Herve" sort="Fridman, Wolf Herve" uniqKey="Fridman W" first="Wolf-Herve" last="Fridman">Wolf-Herve Fridman</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000567 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000567 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     Pascal:12-0259414
   |texte=   Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri